141 related articles for article (PubMed ID: 12880383)
1. Anthrax toxin: structures, functions and tumour targeting.
Liu S; Schubert RL; Bugge TH; Leppla SH
Expert Opin Biol Ther; 2003 Aug; 3(5):843-53. PubMed ID: 12880383
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
3. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Liu S; Bugge TH; Leppla SH
J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
5. Tumor Targeting and Drug Delivery by Anthrax Toxin.
Bachran C; Leppla SH
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376328
[TBL] [Abstract][Full Text] [Related]
6. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
7. Production of recombinant lethal factor of
Gholami M; Moghbeli M; Kafilzadeh F; Kargar M; Torbati MB; Tavizi A; Bellevile S; Hatami J; Eslami Z
Prep Biochem Biotechnol; 2021; 51(1):9-15. PubMed ID: 32393098
[TBL] [Abstract][Full Text] [Related]
8. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
Bardwell AJ; Abdollahi M; Bardwell L
Biochem J; 2004 Mar; 378(Pt 2):569-77. PubMed ID: 14616089
[TBL] [Abstract][Full Text] [Related]
9. Anthrax lethal factor inhibitors as potential countermeasure of the infection.
Kumar BV; Malik S; Grandhi P; Dayam R; Sarma JA
Curr Top Med Chem; 2014; 14(17):1977-89. PubMed ID: 25262802
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
Alfano RW; Leppla SH; Liu S; Bugge TH; Duesbery NS; Frankel AE
Cell Cycle; 2008 Mar; 7(6):745-9. PubMed ID: 18245947
[TBL] [Abstract][Full Text] [Related]
11. Anthrax toxins.
Mourez M
Rev Physiol Biochem Pharmacol; 2004; 152():135-64. PubMed ID: 15549606
[TBL] [Abstract][Full Text] [Related]
12. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.
Tonello F; Montecucco C
Mol Aspects Med; 2009 Dec; 30(6):431-8. PubMed ID: 19665472
[TBL] [Abstract][Full Text] [Related]
13. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
14. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
16. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
17. Anthrax toxin: a tripartite lethal combination.
Ascenzi P; Visca P; Ippolito G; Spallarossa A; Bolognesi M; Montecucco C
FEBS Lett; 2002 Nov; 531(3):384-8. PubMed ID: 12435580
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
19. Anthrax lethal factor proteolysis and inactivation of MAPK kinase.
Chopra AP; Boone SA; Liang X; Duesbery NS
J Biol Chem; 2003 Mar; 278(11):9402-6. PubMed ID: 12522135
[TBL] [Abstract][Full Text] [Related]
20. Toxins of Bacillus anthracis.
Brossier F; Mock M
Toxicon; 2001 Nov; 39(11):1747-55. PubMed ID: 11595637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
